Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested the latest economic data and Trump's response to Canada and EU tariffs. The S&P 500 closed in correction territory.

Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...